Search research articles
Contact Us
Filters
Showing results (81-90 of 135) with videos related to
Page
of 14
Sort By:
Clinical Pharmacology and Therapeutics
|
December 23, 2006
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics
N F Smith, S Marsh, T J Scott-Horton, et al.
Mayo Clinic Proceedings
|
March 9, 1999
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma
J C Buckner, M G Malkin, E Reed, et al.
Blood
|
September 15, 1994
Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study
F M Foss, T A Borkowski, M Gilliom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1997
Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations
E C Kohn, W D Figg, G A Sarosy, et al.
Seminars in Oncology
|
October 31, 2001
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer
W D Figg, P Arlen, J Gulley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 1, 1995
Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction
W D Figg, K A Cole, E Reed, et al.
International Journal of Oncology
|
February 20, 1999
Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo
S W Melchior, L G Brown, W D Figg, et al.
Blood
|
June 15, 1995
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study
E A Sausville, D Headlee, M Stetler-Stevenson, et al.
The Journal of Surgical Research
|
May 19, 2000
The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing
A C Berger, A L Feldman, M F Gnant, et al.
Cancer
|
June 15, 1995
Phase I study of phenylacetate administered twice daily to patients with cancer
A Thibault, D Samid, M R Cooper, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 135) with videos related to
Sort By:
Page
of 14
Clinical Pharmacology and Therapeutics
|
December 23, 2006
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics
N F Smith, S Marsh, T J Scott-Horton, et al.
Mayo Clinic Proceedings
|
March 9, 1999
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma
J C Buckner, M G Malkin, E Reed, et al.
Blood
|
September 15, 1994
Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study
F M Foss, T A Borkowski, M Gilliom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1997
Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations
E C Kohn, W D Figg, G A Sarosy, et al.
Seminars in Oncology
|
October 31, 2001
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer
W D Figg, P Arlen, J Gulley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 1, 1995
Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction
W D Figg, K A Cole, E Reed, et al.
International Journal of Oncology
|
February 20, 1999
Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo
S W Melchior, L G Brown, W D Figg, et al.
Blood
|
June 15, 1995
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study
E A Sausville, D Headlee, M Stetler-Stevenson, et al.
The Journal of Surgical Research
|
May 19, 2000
The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing
A C Berger, A L Feldman, M F Gnant, et al.
Cancer
|
June 15, 1995
Phase I study of phenylacetate administered twice daily to patients with cancer
A Thibault, D Samid, M R Cooper, et al.
Page
of 14